Adverse drug reactions causing cognitive impairment are an important problem in the elderly. 4 key findings →
Participants: 300 Evidence: low
Full summary, score breakdown and related studies → Original source
Research
28,180 Alzheimer's and dementia studies in plain English, each scored out of 100.
Nearly 30% of adults 40 years and older in the United States are on a statin. 1 key finding →
Design: narrative review Evidence: high
Full summary, score breakdown and related studies → Original source
Altogether 153 (60%) out of a sample of 253 people aged 70 years and over living in their own homes were found to have impaired hearing when tested by pure-tone audiometry. 1 key finding →
Participants: 253 Evidence: low
Full summary, score breakdown and related studies → Original source
Our study confirms the strong link between hearing status and the risk of disability, dementia, and depression. 4 key findings →
Participants: 3,777 Evidence: low
Full summary, score breakdown and related studies → Original source
These constituents have shown a reduction in blood glucose levels. 5 key findings →
Participants: 463 Evidence: low
Full summary, score breakdown and related studies → Original source
Age-related hearing loss (ARHL) and dementia are two highly prevalent conditions in the adult population. 2 key findings →
Participants: 488 Evidence: low
Full summary, score breakdown and related studies → Original source
Mutations in the CHCHD10 gene have been recently identified in a large family with a complex phenotype variably associating frontotemporal dementia (FTD) with amyotrophic lateral sclerosis (ALS), cerebellar ataxia, myopathy, and hearing impairment. 1 key finding →
Participants: 115 Evidence: low
Full summary, score breakdown and related studies → Original source
Major depression is more common and more severe in patients with vascular dementia. 3 key findings →
Participants: 124 Evidence: low
Full summary, score breakdown and related studies → Original source
In both the British and French studies, ten health conditions were significantly positively associated with increased Alzheimer's disease risk, in a window of exposure from 2-10 years before Alzheimer's disease diagnosis, comprising major depressive disorder (UK OR 1·34, 95% CI 1·23-1·46; France OR 1·73, 1·57-1·91), anxiety (UK OR 1·36, 1·25-1·47; France OR 1·50, 1·36-1·65), reaction to severe stress and adjustment disorders (UK OR 1·40, 1·24-1·59; France OR 1·83, 1·55-2·15), hearing loss (UK OR 1·19, 1·11-1·28; France OR 1·51, 1·21-1·89), constipation (UK OR 1·31, 1·22-1·41; France OR 1·59, 1·44-1·75), spondylosis (UK OR 1·26, 1·14-1·39; France OR 1·62, 1·44-1·81), abnormal weight loss (UK OR 1·47, 1·33-1·63; France OR 1·88, 1·56-2·26), malaise and fatigue (UK OR 1·23, 1·14-1·32; France OR 1·59, 1·46-1·73), memory loss (UK OR 7·63, 6·65-8·76; France OR 4·41, 3·07-6·34), and syncope and collapse (UK OR 1·23, 1·10-1·37; France OR 1·57, 1·26-1·96). 4 key findings →
Participants: 214 Evidence: low
Full summary, score breakdown and related studies → Original source
To address this, we first examined the prevalence of type 2 diabetes in a community-based controlled study, the Mayo Clinic Alzheimer Disease Patient Registry (ADPR), which follows patients with Alzheimer disease versus control subjects without Alzheimer disease. 2 key findings →
Participants: 100 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Preliminary studies have shown associations between chronic pesticide exposure in occupational settings and neurological disorders. 3 key findings →
Participants: 17,429 Evidence: low
Full summary, score breakdown and related studies → Original source
Of 541 identified studies, 34 were included in the analysis. 5 key findings →
Evidence: high
Full summary, score breakdown and related studies → Original source
Compared to CN counterparts, patients with MCI have higher proportion of families Sclerotiniaceae, Phaffomyceteceae, Trichocomaceae, Cystofilobasidiaceae, Togniniaceae and genera Botrytis, Kazachstania, Phaeoacremonium and Cladosporium and lower abundance of Meyerozyma. 2 key findings →
Evidence: high
Full summary, score breakdown and related studies → Original source
Reliable information on rate of progression of cognitive impairment in probable Alzheimer's disease (AD) is important for evaluating possible beneficial effects of therapeutic agents and in planning long-term care for patients with this chronic illness. 1 key finding →
Participants: 430 Evidence: low
Full summary, score breakdown and related studies → Original source
Statistically significant preoperative factors independently associated with not wearing a prosthesis in order of greatest to least risk were nonambulatory before amputation (OR, 9.5), above knee amputation (OR, 4.4), age > 60 years (OR, 2.7), homebound but ambulatory status (OR, 3.0), presence of dementia (OR, 2.4), end-stage renal disease (OR, 2.3), and coronary artery disease (OR, 2.0). 4 key findings →
Participants: 553 Evidence: low
Full summary, score breakdown and related studies → Original source
Fever episodes in 104 institutionalized patients with Alzheimer's disease were prospectively evaluated to determine the impact of antibiotic treatment on fever outcomes. 3 key findings →
Participants: 75 Evidence: low
Full summary, score breakdown and related studies → Original source
48/100
Mortality patterns in 2007, such as the decline in the age-adjusted death rate to a record historical low, were generally consistent with long-term trends. 1 key finding →
Participants: 2,423,712 Evidence: low
Full summary, score breakdown and related studies → Original source
48/100
In this study, the authors evaluated whether the association between low educational level and increased risk of Alzheimer's disease (AD) and dementia may be explained by occupation-based socioeconomic status (SES). 5 key findings →
Participants: 101 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Growing epidemiological evidence suggests that premorbid participation in cognitive leisure activities (CLA) reduces the risk of dementia by increasing cognitive reserve. 3 key findings →
Participants: 500 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Parkinson's disease (PD), following Alzheimer's disease, is the second-most common neurodegenerative disorder in the United States. 5 key findings →
Participants: 630,000 Evidence: low
Full summary, score breakdown and related studies → Original source
Just under a half of the expected numbers of patients with dementia are recognised in GP dementia registers. 4 key findings →
Participants: 351 Evidence: low
Full summary, score breakdown and related studies → Original source
Although persons with dementia are frequently hospitalized, relatively little is known about the health profile, patterns of health care use, and mortality rates for patients with dementia who access care in the emergency department (ED). 4 key findings →
Participants: 10,354 Evidence: low
Full summary, score breakdown and related studies → Original source
Progressive atrophy was revealed in presymptomatic individuals, with posterior cingulate and neocortical temporoparietal cortical losses, and medial temporal-lobe atrophy. 1 key finding →
Participants: 20 Evidence: low
Full summary, score breakdown and related studies → Original source
Normalized thickness index at baseline differed significantly among all the four diagnosis groups (P < 0.001) and correctly distinguished Alzheimer's disease patients from healthy controls with an 85% cross-validated accuracy. 2 key findings →
Participants: 122 Evidence: low
Full summary, score breakdown and related studies → Original source
Neurodegenerative diseases are associated with profound changes in social and emotional function. 3 key findings →
Participants: 148 Evidence: low
Full summary, score breakdown and related studies → Original source
Where “Free full text” comes from
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
How the 0–100 score works — and why some entries are capped
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
- Journal tier up to 10 pts
- Journal's citation record up to 4 pts
- Study design up to 12 pts
- Strength of evidence up to 5 pts
- Peer-review validation up to 10 pts
- How recent up to 5 pts
- Sample size up to 4 pts
- Effect reported up to 3 pts
- Studied in people up to 3 pts
- Randomised / blinded up to 2 pts
- Times cited up to 7 pts
- Citations per year up to 5 pts
- Impact for its field and year up to 6 pts
- Cited by studies here up to 6 pts
- Still being cited up to 4 pts
- Senior author's track record up to 4 pts
- Institution's track record up to 3 pts
- Multi-centre collaboration up to 3 pts
- Indexed in PubMed up to 2 pts
- Free to read up to 2 pts
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 28,180 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
What this library is — and isn't
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 28,180 records, built mostly from automated pulls of Europe PMC (61.7% of the library) and OpenAlex (18.1%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,034 records (3.7% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →